![CEimpact Podcast artwork](https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/5e/ae/42/5eae4208-b706-0adc-12fb-75292fc9ea63/mza_14075584767013252581.jpg/100x100bb.jpg)
Is the Price Right for Aducanumab?
CEimpact Podcast
English - July 27, 2021 09:00 - 37 minutes - 25.7 MBCourses Education Science ceimpact podcast precept2practice level up gamechangers pharmacy cme cpe pharmacology ceimpact geoff wall Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
The first new treatment for Alzheimer's, aducanumab, was approved by the Food and Drug Administration on June 7, 2021. This approval did not come without controversy. Learn what the available data show for efficacy and safety and whether or not the current list price of $56,000 per year meets cost-effectiveness thresholds.
Guest
John A Galdo, PharmD, MBA, BCPS, BCGP
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad
Redeem your CPE or CME credit here!
We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964
References and resources:
Aducanumab for Alzheimer's Disease: Effectiveness and Value. Institute for Clinical and Economic Review. June 30, 2021. https://icer.org/wp-content/uploads/2020/10/ICER_ALZ_Revised_Evidence_Report_06302021.pdf
Continuing Education Information:
Learning Objectives:
1. Discuss the outcomes for phase III trials of aducanumab
2. Define the cost-effectiveness of aducanumab
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-265-H01-P
Initial release date: 7/27/21
Expiration date: 7/27/22
John A. Galdo reports that he is on a speaker's bureau for Novo Nordisk.
Complete CPE & CME details can be found here.